FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024432964> ?p ?o ?g. }

• W2024432964 endingPage "611" @default.
• W2024432964 startingPage "603" @default.
• W2024432964 abstract "The treatment of choice for most cases of non-small-cell lung cancer is surgical resection; however, which patients with stage IIIA disease are surgical candidates is debatable. For many patients with stage IIIA or IIIB disease, the preferred modality is thoracic radiotherapy. In several randomized prospective trials, the addition of chemotherapy to thoracic radiotherapy produced a significant but clinically small survival advantage over radiotherapy alone. For patients with stage IV lung cancer, no curative treatment or “standard therapy” is available. Accordingly, many patients are offered investigational agents in phase I or II clinical trials. Small-cell lung cancer has a 60 to 90% rate of initial response to available chemotherapeutic agents. Patients with limited disease are generally given combination chemotherapy and thoracic radiotherapy, approximately 50% of whom have a complete clinical remission. Patients with extensive disease (spread beyond one radiation port) also have a high rate of initial response to chemotherapy, but only 20 to 40% have a complete remission and few survive for 5 years. New agents are being tested in previously untreated patients with extensive small-cell lung cancer. Promising new chemotherapeutic agents for lung cancer are being studied in clinical trials. Currently, only 1% of patients with lung cancer in the United States are enrolled in prospective clinical trials. Primary-care physicians are urged to encourage their patients to consider participation in approved prospective clinical trials at reputable medical centers, in an effort to discover new, effective agents with novel mechanisms of action. Information about such studies is available through Physician Desk Query (PDQ) or the cancer hotline (1-800-4-CANCER). The treatment of choice for most cases of non-small-cell lung cancer is surgical resection; however, which patients with stage IIIA disease are surgical candidates is debatable. For many patients with stage IIIA or IIIB disease, the preferred modality is thoracic radiotherapy. In several randomized prospective trials, the addition of chemotherapy to thoracic radiotherapy produced a significant but clinically small survival advantage over radiotherapy alone. For patients with stage IV lung cancer, no curative treatment or “standard therapy” is available. Accordingly, many patients are offered investigational agents in phase I or II clinical trials. Small-cell lung cancer has a 60 to 90% rate of initial response to available chemotherapeutic agents. Patients with limited disease are generally given combination chemotherapy and thoracic radiotherapy, approximately 50% of whom have a complete clinical remission. Patients with extensive disease (spread beyond one radiation port) also have a high rate of initial response to chemotherapy, but only 20 to 40% have a complete remission and few survive for 5 years. New agents are being tested in previously untreated patients with extensive small-cell lung cancer. Promising new chemotherapeutic agents for lung cancer are being studied in clinical trials. Currently, only 1% of patients with lung cancer in the United States are enrolled in prospective clinical trials. Primary-care physicians are urged to encourage their patients to consider participation in approved prospective clinical trials at reputable medical centers, in an effort to discover new, effective agents with novel mechanisms of action. Information about such studies is available through Physician Desk Query (PDQ) or the cancer hotline (1-800-4-CANCER)." @default.
• W2024432964 created "2016-06-24" @default.
• W2024432964 creator A5058147268 @default.
• W2024432964 date "1993-06-01" @default.
• W2024432964 modified "2023-09-25" @default.
• W2024432964 title "Current Treatment of Unresectable Lung Cancer" @default.
• W2024432964 cites W1444632987 @default.
• W2024432964 cites W1780841930 @default.
• W2024432964 cites W1856909224 @default.
• W2024432964 cites W1884032213 @default.
• W2024432964 cites W1898303405 @default.
• W2024432964 cites W1909306097 @default.
• W2024432964 cites W1922104747 @default.
• W2024432964 cites W1923792259 @default.
• W2024432964 cites W1935482218 @default.
• W2024432964 cites W1962075013 @default.
• W2024432964 cites W1962175162 @default.
• W2024432964 cites W1965309018 @default.
• W2024432964 cites W1967655634 @default.
• W2024432964 cites W1975549289 @default.
• W2024432964 cites W1978156658 @default.
• W2024432964 cites W1989315499 @default.
• W2024432964 cites W1991915284 @default.
• W2024432964 cites W1995606594 @default.
• W2024432964 cites W1995686464 @default.
• W2024432964 cites W2002873037 @default.
• W2024432964 cites W2013582820 @default.
• W2024432964 cites W2016691736 @default.
• W2024432964 cites W2026516286 @default.
• W2024432964 cites W2026848003 @default.
• W2024432964 cites W2034840803 @default.
• W2024432964 cites W2038042148 @default.
• W2024432964 cites W2040406891 @default.
• W2024432964 cites W2061961646 @default.
• W2024432964 cites W2064844362 @default.
• W2024432964 cites W2067719172 @default.
• W2024432964 cites W2086712510 @default.
• W2024432964 cites W2088304511 @default.
• W2024432964 cites W2088766047 @default.
• W2024432964 cites W2089063479 @default.
• W2024432964 cites W2097597328 @default.
• W2024432964 cites W2103926757 @default.
• W2024432964 cites W2117756825 @default.
• W2024432964 cites W2122995772 @default.
• W2024432964 cites W2127061702 @default.
• W2024432964 cites W2138310931 @default.
• W2024432964 cites W2138945505 @default.
• W2024432964 cites W2178828310 @default.
• W2024432964 cites W2180031316 @default.
• W2024432964 cites W2226077283 @default.
• W2024432964 cites W2228760793 @default.
• W2024432964 cites W2231032834 @default.
• W2024432964 cites W2236604469 @default.
• W2024432964 cites W2242204182 @default.
• W2024432964 cites W2262115948 @default.
• W2024432964 cites W2273228267 @default.
• W2024432964 cites W2291356857 @default.
• W2024432964 cites W2312703485 @default.
• W2024432964 cites W2317448174 @default.
• W2024432964 cites W2410451535 @default.
• W2024432964 cites W4231647528 @default.
• W2024432964 cites W4301015771 @default.
• W2024432964 cites W4321060907 @default.
• W2024432964 cites W4360754102 @default.
• W2024432964 cites W4375906069 @default.
• W2024432964 doi "https://doi.org/10.1016/s0025-6196(12)60376-0" @default.
• W2024432964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8388526" @default.
• W2024432964 hasPublicationYear "1993" @default.
• W2024432964 type Work @default.
• W2024432964 sameAs 2024432964 @default.
• W2024432964 citedByCount "47" @default.
• W2024432964 countsByYear W20244329642012 @default.
• W2024432964 countsByYear W20244329642013 @default.
• W2024432964 countsByYear W20244329642014 @default.
• W2024432964 countsByYear W20244329642015 @default.
• W2024432964 countsByYear W20244329642017 @default.
• W2024432964 countsByYear W20244329642019 @default.
• W2024432964 countsByYear W20244329642020 @default.
• W2024432964 crossrefType "journal-article" @default.
• W2024432964 hasAuthorship W2024432964A5058147268 @default.
• W2024432964 hasConcept C121608353 @default.
• W2024432964 hasConcept C126322002 @default.
• W2024432964 hasConcept C141071460 @default.
• W2024432964 hasConcept C143998085 @default.
• W2024432964 hasConcept C146357865 @default.
• W2024432964 hasConcept C151730666 @default.
• W2024432964 hasConcept C2776256026 @default.
• W2024432964 hasConcept C2776694085 @default.
• W2024432964 hasConcept C2779134260 @default.
• W2024432964 hasConcept C509974204 @default.
• W2024432964 hasConcept C535046627 @default.
• W2024432964 hasConcept C71924100 @default.
• W2024432964 hasConcept C86803240 @default.
• W2024432964 hasConceptScore W2024432964C121608353 @default.
• W2024432964 hasConceptScore W2024432964C126322002 @default.
• W2024432964 hasConceptScore W2024432964C141071460 @default.
• W2024432964 hasConceptScore W2024432964C143998085 @default.
• W2024432964 hasConceptScore W2024432964C146357865 @default.

• next